Forte Biosciences, Inc. Common Stock Shares Outstanding

• Forte Biosciences, Inc. showed an increase of +102.5% in Common Stock Shares Outstanding from 2024 to 2025.
• This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: 2.23 million shares | Q2 2017: 19.81 million shares | Q3 2017: 19.81 million shares | Q1 2018: 19.91 million shares | Q2 2018: 19.95 million shares | Q3 2018: 19.95 million shares | Q1 2019: 23.21 million shares | Q2 2019: 23.90 million shares | Q3 2019: 23.90 million shares | Q1 2020: 23.91 million shares | Q2 2020: 11.20 million shares | Q3 2020: 11.22 million shares | Q1 2021: 13.51 million shares | Q2 2021: 14.08 million shares | Q3 2021: 14.75 million shares | Q1 2022: 14.76 million shares | Q2 2022: 14.76 million shares | Q3 2022: 21.00 million shares | Q1 2023: 21.01 million shares | Q2 2023: 21.05 million shares | Q3 2023: 36.28 million shares | Q1 2024: 36.39 million shares | Q2 2024: 36.44 million shares | Q3 2024: 1.46 million shares | Q1 2025: 6.58 million shares | Q2 2025: 12.28 million shares | Q3 2025: 12.52 million shares.
• Over the full 10 years of available data (2016 to 2025), Forte Biosciences, Inc.'s Common Stock Shares Outstanding has grown by 487.9%.
• Historical annual values: Fiscal year 2025: 12.95 million shares | Fiscal year 2024: 6.39 million shares | Fiscal year 2023: 1.45 million shares | Fiscal year 2022: 21.00 million shares | Fiscal year 2021: 14.75 million shares | Fiscal year 2020: 12.83 million shares | Fiscal year 2019: 2.11 million shares | Fiscal year 2018: 23.00 million shares | Fiscal year 2017: 19.88 million shares | Fiscal year 2016: 2.20 million shares.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026